Technical Analysis for BBIO - BridgeBio Pharma, Inc.

Grade Last Price % Change Price Change
grade B 27.46 2.62% 0.70
BBIO closed up 2.62 percent on Friday, August 16, 2019, on 81 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent N/A N/A Flat
See historical BBIO trend table...

Date Alert Name Type % Chg
20 DMA Resistance Bearish 0.00%
Strong but Oversold Other 0.00%
Oversold Stochastic Weakness 0.00%
Bullish Engulfing Bullish 2.62%
Stochastic Buy Signal Bullish 2.62%
Oversold Stochastic Weakness 2.62%
New 52 Week Closing Low Bearish 6.06%
NR7 Range Contraction 6.06%
NR7-2 Range Contraction 6.06%
Lower Bollinger Band Touch Weakness 6.06%

Older signals for BBIO ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
BridgeBio Pharma, Inc. engages in developing transformative medicines to treat patients who suffer from mendelian diseases. Its pipeline of 15 development programs includes product candidates from early discovery to late-stage development. The firm develops BBP-265, an oral small molecule transthyretin for the treatment of TTR amyloidosis, including cardiomyopathy and polyneuropathy manifestations; infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor for the treatment of FGFR-driven cancers and in preclinical development for the treatment of achondroplasia; and BBP-631, a preclinical adeno-associated virus, gene transfer product candidate, for the treatment of congenital adrenal hyperplasia caused by 21OHD. The company was founded by Charles Homcy, Frank McCormick, Philip Reilly and Neil Kumar on May 17, 2019 and is headquartered in Palo Alto, CA.
Organ Systems Anatomy Tyrosine Kinase Receptors Protein Kinase Inhibitor Cardiomyopathy Tyrosine Kinase Familial Amyloid Polyneuropathy Hyperplasia Achondroplasia Congenital Adrenal Hyperplasia Fibroblast Growth Factor Receptor Transthyretin TTR Amyloidosis
Is BBIO a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 0 bearish and 4 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 32.812
52 Week Low 24.0556
Average Volume 269,195
200-Day Moving Average 0.0
50-Day Moving Average 0.0
20-Day Moving Average 28.013
10-Day Moving Average 27.401
Average True Range 2.1322
ADX 8.57
+DI 23.8685
-DI 20.4289
Chandelier Exit (Long, 3 ATRs ) 26.4154
Chandelier Exit (Short, 3 ATRs ) 30.4522
Upper Bollinger Band 30.5472
Lower Bollinger Band 25.4788
Percent B (%b) 0.39
BandWidth 18.093028
MACD Line -0.2289
MACD Signal Line -0.0391
MACD Histogram -0.1897
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 30.07
Resistance 3 (R3) 30.07 29.19 29.64
Resistance 2 (R2) 29.19 28.53 29.20 29.49
Resistance 1 (R1) 28.33 28.12 28.76 28.33 29.34
Pivot Point 27.45 27.45 27.67 27.46 27.45
Support 1 (S1) 26.59 26.79 27.02 26.59 25.58
Support 2 (S2) 25.71 26.38 25.72 25.43
Support 3 (S3) 24.85 25.71 25.29
Support 4 (S4) 24.85